1.
Castro M, Conn DL, Su DWP, Garton JP: Rheumatic manifestations in myelodysplastic syndromes. J Rheumatol 1991;18:721–727.
2.
Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA: Immunological abnormalities in myelodysplastic syndromes. Br J Haematol 1986;63:143–147.
3.
Green AR, Shuttleworth D, Bowen DT, Bentley DP: Cutaneous vasculitis in patients with myelodysplasia. Br J Haematol 1990;74:364–365.
4.
Savige JA, Smith CL, Chang L, Duggan JC: Anti-neutrophil cytoplasmic antibodies in myelodysplasia and other haematological disorders. Aust NZ J Med 1994;24:282–287.
5.
Lossos IS, Bogomolski-Yahalom V, Matzner Y: Anticardiolipin antibodies in acute myeloid leukemia: Prevalence and clinical significance. Am J Hematol 1998;57:139–143.
6.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Suultan C, The French-American-British (FAB) Co-operative Group: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189–199.
7.
Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN: Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust NZ J Med 1990;20:231–236.
8.
Harris EN, Gharavi AE, Patel SP, Hughes GRV: Evaluation of the anticardiolipin antibody test: Report of an international workshop held 4 April 1986. Clin Exp Immunol 1987;68:215–222.
9.
Bynoe AG, Scott PF, Roberts BE: Decreased T helper cells in the MDS. Br J Haematol 1983;54:97–102.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or...
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.